Site Loader

has decided to embark on the path of fine-tuning and developing rhNGF in its formulation for clinical use, at its own biotech facility in L’Aquila. and in Naples, where there are the laboratories of Drug Discovery and Technology Formulation, within a long-term collaboration with CNR. Italian excellence: the Dompé Hub in L’Aquila. Dompé has concentrated its manufacturing and research and development activities at its L’Aquila hub.

Author: Megore Mazudal
Country: Saint Lucia
Language: English (Spanish)
Genre: Politics
Published (Last): 7 January 2013
Pages: 289
PDF File Size: 14.12 Mb
ePub File Size: 17.37 Mb
ISBN: 949-2-88821-985-8
Downloads: 53482
Price: Free* [*Free Regsitration Required]
Uploader: Zulugis

DrugsOrganic ChemistryFda.

Cenegermin is a human beta-nerve growth factor beta-ngf – – peptide non-covalent dimer produced in escherichia coli. At this point, the bacterial cells are separated from the cultivation broth, concentrated and recovered through a continuous centrifuge in order to separate the cells from the other residual organic material of the fermentation.

Regarded as among the world’s foremost experts on corneal diseases, he was appointed Adjunct Assistant Professor of Biology at Temple University of Philadelphia. The production of liquids refers to the two lines of formulation and packaging known as small and large volume.

DOMPE « New Drug Approvals

We suggest you to update it for free by following one of the these links, choosing the browser you prefer: The chemokine CXCL8 dompr a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after organ transplantion.

Rormulation production process for granules includes an initial phase of dispensing weighing of the raw materials active ingredient and excipients. A constantly evolving reality in which talent can thrive. The current annual production capacity is 50 million packs. The 3D structure of rhNGF is a non-covalent dimer with three intra-molecular disulphide bridges.

The production lines are continuously being updated and expanded, as a consequence of the increased demand for products for the Italian and international market and the continuous need for harmonisation with current international standards.


Accessing the formulahion you have selected you will be subject to the terms of use of this last. Reparixin is the first low molecular weight blocker of CXCL8 biological activity in clinical development. This site uses third party cookies.

L’Aquila hub

The packaging is divided into two phases. Several laboratories are up and running at CDMO, for analytical development and quality control, making it possible to conduct the most in-depth analyses in the biotechnology field.

In the Biotech BU, Marketing staff handles products for rare therapeutic indications and speciality care products. The activities being implemented included continuous control, through dom;e monitoring network consisting of 1, elements SCADA that monitor the areas and production facilities.

The collaborations in the territory have the objective of creating new knowledge and developing suitable expertise for the profound technological and innovative transformation that is revolutionizing the health sector worldwide. Fkrmulation using Artificial Intelligence odmpe Neural Networks, Fuzzy Logic are also under way at the facility for analysing and optimizing certain production processes.

By continuing to use this web site, you are consenting to the use of cookies. Follow Blog via Email Enter your email address to follow this blog and receive notifications of new posts by email. It acts as an inhibitor of IL-8, a molecule involved in the inflammatory processes leading to the progressive autoimmune destruction of the cells of the islets of Langerhans in type 1 diabetes.

The entire process is constantly overseen by a working group composed of researchers who work in very close contact with the Chemical Analysis Department. For information, including how to block the cookies, click here. The plasmid is thus inserted inside the bacterium, from which the clone is generated in order to genetically produce the cell bank made up of numerous test-tubes containing numerous genetically equal bacteria in suspension.

By continuing to use this web site, you are consenting to the use of cookies. This site uses third party cookies. The most common adverse reactions in patients taking Oxervate are eye pain, ocular hyperemia enlarged blood vessels in the white of the eyeseye inflammation and increased lacrimation watery eyes. In the first part of the downstream process, the inclusion bodies, coming from the upstream phase, are solubilised and then the folding phase starts.


This non-stop development and implementation facility hosts two production lines dedicated to packets, three lines dedicated to sticks, one line for syrups and one line for dosed vials.

You are going to leave this site. Click here to learn more. Across both studies, complete corneal healing in eight weeks was demonstrated in 70 percent of patients treated with Oxervate compared to 28 percent of patients treated without cenegermin the active dope in Oxervate.

Post was not sent – check your email addresses! For information, including how to block the cookies, click here. For information, including how to block the dpmpe, click here. This phase is followed by packaging in boxes, wrapping and pallets.

Home Research and Innovation An Italian excellence. In particular the study dealt with the mathematical modelling of the biotech fermentation process for the production of NGF having used AI techniques. We suggest you to update it for free by following one of the these links, choosing the browser you prefer: The hub employs 70 researchers and now, thanks to the special technical and scientific skills accumulated over the fogmulation, the facility is able to cover the entire Drug Discovery process, from the initial research stages formulationn to final clinical development.